Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

FLT3 targeting in the modern era: from clonal selection to combination therapies.

International journal of hematology - 1 Nov 2024

Kennedy Vanessa E, Smith Catherine C

Abstract excerpt

Fms-like tyrosine kinase 3 (FLT3) is the most frequently mutated gene in acute myeloid leukemia (AML). Modern targeting of FLT3 with inhibitors has improved clinical outcomes and FLT3 inhibitors have been incorporated into the treatment of AML in all phases of the disease, including the upfront, relapsed/refractory and maintenance settings. This review will discuss the current understanding of FLT3 biology, the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Myeloid Leukemia Research
Share to Antineoplastic Combined Chemotherapy Protocols

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Drug Resistance, Neoplasm

Share to fms-Like Tyrosine Kinase 3

Share to Leukemia, Myeloid, Acute

Share to Molecular Targeted Therapy

Share to Mutation

Share to Protein Kinase Inhibitors

Source

Open in PubMed Open full text

Identifiers

PMID: 38112995
DOI: 10.1007/s12185-023-03681-0
PMCID: PMC11513752

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

FLT3 targeting in the modern era: from clonal selection to combination therapies.PMID 38112995Read ↗

Targeting FLT3 Mutations in Acute Myeloid LeukemiaSemantic proximity Read ↗

FLT3 inhibitors and novel therapeutic strategies to reverse AML resistance: An updated comprehensive review.Semantic proximity Read ↗

Targeting the FMS-like tyrosine kinase 3 in acute myeloid leukemia.Semantic proximity Read ↗

Therapeutic targeting of FLT3 and associated drug resistance in acute myeloid leukemia.Semantic proximity Read ↗

Strategies targeting FLT3 beyond the kinase inhibitors.Semantic proximity Read ↗

Targeting FLT3 to treat leukemia.Semantic proximity Read ↗

FLT3-targeted treatment for acute myeloid leukemia.Semantic proximity Read ↗

FLT3 signaling and the development of inhibitors that target FLT3 kinase activity.Semantic proximity Read ↗

Targeting FMS-like tyrosine kinase 3 (FLT3) in acute myeloid leukemia: Novel molecular approaches and therapeutic challengesSemantic proximity Read ↗

Recent Advances in FLT3 Inhibitors for Acute Myeloid LeukemiaSemantic proximity Read ↗

Tyrosine kinase inhibitors targeting FLT3 in the treatment of acute myeloid leukemiaSemantic proximity Read ↗

Developments and challenges of FLT3 inhibitors in acute myeloid leukemiaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.